A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 64, Issue 7, 2017, Pages

  Finkelstein, Yaron ^a   Blonquist, Traci M ^b   Vijayanathan, Veena ^c   Stevenson, Kristen E ^b   Neuberg, Donna S ^b   Silverman, Lewis B ^b,d,e   Vrooman, Lynda M ^b,d,e   Sallan, Stephen E ^b,d,e   Cole, Peter D ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

acute lymphoblastic leukemia; avascular necrosis; fracture; methotrexate; osteonecrosis; therapy related toxicity

Indexed keywords

FOLINIC ACID; GENOMIC DNA; GLUCOCORTICOID; METHOTREXATE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; ASPARAGINASE;

5' UNTRANSLATED REGION; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE NECROSIS; CANCER CHEMOTHERAPY; CHILD; CLINICAL TRIAL; CORTICOSTEROID METABOLISM; FEMALE; FRACTURE; GENE; GENE TARGETING; GENETIC RISK; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; NUCLEOTIDE REPEAT; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THYMIDYLATE SYNTHASE GENE; CHEMICALLY INDUCED; CONTROLLED STUDY; GENETIC PREDISPOSITION; GENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; FEMALE; FRACTURES, BONE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHOTREXATE; OSTEONECROSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THYMIDYLATE SYNTHASE;

EID: 85019559655     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26393     Document Type: Article

References (41)

1. Hudson MM, Link MP, Simone JV. Milestones in the curability of pediatric cancers. J Clin Oncol. 2014;32(23):2391–2397.
2. Pui C-H, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: Progress through collaboration. J Clin Oncol. 2015;33(27):2938–2948.
3. Kawedia JD, Kaste SC, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117(8):2340–2347.
4. Niinimäki T, Harila-Saari A, Niinimäki R. The diagnosis and classification of osteonecrosis in patients with childhood leukemia. Pediatr Blood Cancer. 2015;62(2):198–203.
5. Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study—Dana-Farber Cancer Institute ALL Consortium Protocol 00–01. J Clin Oncol. 2013;31(9):1202–1210.
6. Mattano LA Jr., Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol. 2000;18(18):3262–3272.
7. Girard P, Auquier P, Barlogis V, et al. Symptomatic osteonecrosis in childhood leukemia survivors: Prevalence, risk factors and impact on quality of life in adulthood. Haematologica. 2013;98(7):1089–1097.
8. Mattano LA, Devidas M, Chen S, et al. Effect of high-dose methotrexate (HD-MTX) vs capizzi methotrexate/pegaspargase (C-MTX/ASNase) on osteonecrosis (ON) incidence in children and young adults with T-acute lymphoblastic leukemia (T-ALL): Results of Children's Oncology Group (COG) study AALL0434. Blood. 2014;124(21):3649–3649.
9. Badhiwala JH, Nayiager T, Athale UH. The development of thromboembolism may increase the risk of osteonecrosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(10):1851–1854.
10. Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012;26(11):2303–2309.
11. Georgiou KR, Scherer MA, Fan C-M, et al. Methotrexate chemotherapy reduces osteogenesis but increases adipogenic potential in the bone marrow. J Cell Physiol. 2012;227(3):909–918.
12. Karol SE, Yang W, Van Driest SL, et al. Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2015;126(15):1770–1776.
13. Bond J, Adams S, Richards S, Vora A, Mitchell C, Goulden N. Polymorphism in the PAI-1 (SERPINE1) gene and the risk of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;118(9):2632–2633.
14. French D, Hamilton LH, Mattano LA Jr, et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood. 2008;111(9):4496–4499.
15. Relling MV, Yang W, Das S, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol. 2004;22(19):3930–3936.
16. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): A randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677–1690.
17. Deng FY, Tan LJ, Shen H, et al. SNP rs6265 regulates protein phosphorylation and osteoblast differentiation and influences BMD in humans. J Bone Miner Res. 2013;28(12):2498–2507.
18. Eriksson AL, Mellström D, Lorentzon M, et al. The COMT val158met polymorphism is associated with prevalent fractures in Swedish men. Bone. 2008;42(1):107–112.
19. Cashman KD. Homocysteine and osteoporotic fracture risk: A potential role for B vitamins. Nutr Rev. 2005;63(1):29–36.
20. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1(2):99–108.
21. Nandar W, Neely EB, Unger E, Connor JR. A mutation in the HFE gene is associated with altered brain iron profiles and increased oxidative stress in mice. Biochim Biophys Acta. 2013;1832(6):729–741.
22. Olsson S, Holmegaard L, Jood K, et al. Genetic variation within the interleukin-1 gene cluster and ischemic stroke. Stroke. 2012;43(9):2278–2282.
23. Goode EL, Potter JD, Bigler J, Ulrich CM. Methionine synthase D919G polymorphism, folate metabolism, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2004;13(1):157–162.
24. Krajinovic M, Robaey P, Chiasson S, et al. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics. 2005;6(3):293–302.
25. Cole PD, Finkelstein Y, Stevenson KE, et al. Polymorphisms in genes related to oxidative stress are associated with inferior cognitive function after therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2015;33(19):2205–2211.
26. Fleury I, Primeau M, Doreau A, et al. Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia. Am J Pharmacogenomics. 2004;4(5):331–341.
27. Mödder UI, Achenbach SJ, Amin S, et al. Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res. 2010;25(2):415–422.
28. Obeid R, Kostopoulos P, Knapp JP, et al. Biomarkers of folate and vitamin B12 are related in blood and cerebrospinal fluid. Clin Chem. 2007;53(2):326–333.
29. Li Y, Vijayanathan V, Gulinello ME, Cole PD. Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats. Pharmacol Biochem Behav. 2010;94(3):454–463.
30. Vijayanathan V, Smith AK, Zebala JA, High-performance liquid chromatography separation of aminopterin-polyglutamates within red blood cells of children treated for acute lymphoblastic leukemia. Trans Res. 2007;150(6):367–373.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statis Assoc. 1958;53(282):457–481.
32. Kahn J, Barrera S, Davila R, et al. Higher incidence of treatment-related toxicities in non-Hispanic patients undergoing therapy for newly diagnosed pediatric acute lymphoblastic leukemia on Dana-Farber Cancer Institute All Consortium Protocol 05-001. Blood. 2015;126(23):248–248.
33. Waisman HA, Harvey RA. Radiological evidence of growth in children with acute leukemia treated with folic acid antagonists. Radiology. 1954;62(1):61–64.
34. Allegra CJ, Chabner BA, Drake JC. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem. 1985;260(17):9720–9726.
35. Kawakami K, Salonga D, Park JM, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res. 2001;7(12):4096–4101.
36. Cole PD, Zebala JA, Alcaraz MJ, Pharmacodynamic properties of methotrexate and aminotrexate during weekly therapy. [erratum appears in Cancer Chemother Pharmacol. 2006;58(3):418 Note: Zebala, John A [added]]. Cancer Chemother Pharmacol. 2006;57(6):826–834.
37. Graham ML, Shuster JJ, Kamen BA, et al. Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: A pediatric oncology group pilot study. Cancer Chemother Pharmacol. 1992;31(3):217–222.
38. Salzer WL, Winick NJ, Wacker P, et al. Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2012;34(1):e1–e7.
39. Molloy AM, Kirke PN, Brody LC, Effects of folate and vitamin B12 deficiencies during pregnancy on fetal, infant, and child development. Food Nutr Bull. 2008;29(2 suppl):S101–S111.
40. Tobias J, Steer C, Emmett P, et al. Bone mass in childhood is related to maternal diet in pregnancy. Osteoporos Int. 2005;16(12):1731–1741.
41. McLean RR, Karasik D, Selhub J, et al. Association of a common polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene with bone phenotypes depends on plasma folate status. J Bone Miner Res. 2004;19(3):410–418.